Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(5):343-346
DOI: DOI:10.5428/pcar20180507
Effects of levetiracetam treatment on the patients with first diagnosed epilepsy and bone metabolism and bone mineral density
1. WAN Qi(Department of Neurology,No.101 Hospital of PLA,Wuxi Jiangsu 214044,China wqqw101@sina.com)
2. WU JiaYu(Department of Neurology,No.101 Hospital of PLA,Wuxi Jiangsu 214044,China Wxcabt101@163.com)
3. CAO JunDong(Department of Neurology,No.101 Hospital of PLA,Wuxi Jiangsu 214044,China )
4. ZHU Jin(Department of Neurology,No.101 Hospital of PLA,Wuxi Jiangsu 214044,China )
ABSTRACT  Objective: To investigate the curative effects of levetiracetam on the patients with first diagnosed epilepsy, as well as bone metabolism and bone mineral density (BMD). Methods: Totally, 66 cases of first diagnosed epilepsy treated in No. 101 Hospital of PLA from June 2015 to May 2017 were enrolled as study subjects, and were divided into group A (with levetiracetam treatment, n=33) and group B (with carbamazepine treatment, n=33). The curative effects, adverse drug reactions (ADRs), bone metabolism and BMD before treatment and 6 months after treatment were compared between the patients of the 2 groups. Results: Total effective rate of the patients in group A and group B was not statistically different. The rates of dizziness, headache, drowsiness, nausea and vomiting, hepatic function injury and mood change in the patients of both groups were also not statistically different. There was no statistical significance in the levels of serum calcium, phosphorus, alkaline phosphatase and parathyroid hormone, when comparisons were made between the 2 groups before treatment. However, 6 months after treatment, the level of serum calcium in group B was lower than that of group A, and was also lower than that of itself before treatment. The levels of serum phosphorus and alkaline phosphatase in group B were higher than those of group A and were also higher than those itself before treatment (P<0.05). Before treatment, there was no statistical significance in the bone mass density of lumbar vertebrae, femoral trochanter, femoral neck and Ward triangle in the 2 groups. However, after 6 months of treatment, the BMD of femoral trochanter, femoral neck and Ward triangle of group B decreased significantly, as compared with that before treatment (P<0.05), while for the patients of group A, there were no statistical differences in the BMD of these sites, when comparisons were made with those before treatment (P>0.05). Conclusion: Levetiracetam in the treatment of patients with first diagnosed epilepsy could produce significant curative effects with high medication safety. Furthermore, it could lower the impact on bone metabolism and BMD, as compared with carbamazepine.
Welcome to PCAR! You are the number 42 reader of this article!
Please cite this article as:
WAN Qi,WU JiaYu,CAO JunDong,ZHU Jin,. Effects of levetiracetam treatment on the patients with first diagnosed epilepsy and bone metabolism and bone mineral density[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(5): 343-346.
References:
1. Yilmaz K, Karatoprak E Y. Epilepsy classification and additional definitions in occipital lobe epilepsy[J]. Epileptic Disord, 2015,17(3):299-307.
2. LU YunFeng, Worrell G A, Zhang H C, et al.Noninvasive imaging of the high frequency brain activity in focal epilepsy patients[J]. IEEE Trans Biomed Eng,2014,61(6):1660-1667.
3. LI ManTang. Correlation between epilepsy and bone metabolism in adults[J]. Chin Gen Pract,2017,20(25):3140-3143. In Chinese with English abstract.
4. MA ShuFang, ZOU LiPing. Progress in the study of the relationship between epilepsy and bone metabolism[J]. Chin J Health Care Med,2017,19(2):180-181. In Chinese.
5. Schiecke K, Wacker M, Piper D, et al.Time-variant, frequency-selective, linear and nonlinear analysis of heart rate variability in children with temporal lobe epilepsy[J]. IEEE Trans Biomed Eng,2014,61(6):1798-1808.
6. CAO ZhiHua, ZHOU PeiYang, HONG Yan. Effect of antiepileptic drugs on bone mineral density in patients with epilepsy[J]. Chin J Pract Nerv Dis,2016,19(8):90-91. In Chinese.
7. ZHANG Fang, LI GuiXin. Effect of antiepileptic drugs on bone metabolism and quality of life in children with epilepsy[J]. Shaanxi Med J,2016,45(1):28-30. In Chinese.
8. Losurdo A,Proserpio P, Cardinale F,et al.Drug-resistant focal sleep related epilepsy: results and predictors of surgical outcome[J].Epilepsy Res,2014,108(5):953-962.
9. CHEN KaiJie, ZHOU KaiQin, FANG GuangCui, et al. Blood concentration monitoring of carbamazepine in epileptic patients and analysis of its influential factors[J]. China Pharmaceuticals, 2015,24(21):60-62. In Chinese with English abstract.
10. HUANG Wei. Comparisons of efficacy and adverse drug reactions of carbamazepine plus valproate and carbamazepine alone in the treatment of epilepsy[J]. Chin J Pract Nerv Dis,2016,19(14):119-120. In Chinese.
11. LI LongKuan, Xie Juan, ZHANG LingMin, et al. Effects of oxcarbazepine and levetiracetam on plasma concentrations of valproic acid and its metabolite 2-propyl-2-pentenoic acid in epileptic children[J]. Chin Hosp Pharm J,2016,36(1):41-45. In Chinese with English abstract.
12. YANG JunBao, WANG XiaoDong, LIU LingHui. Effect of carbamazepine on cognitive function and mood in elderly patients with epilepsy[J]. Chin J Gerontol,2016,36(3):627-628. In Chinese.
13. ZHANG ShouLi, MO YaLing, ZHAO DeYun, et al. Clinical effect of levetiracetam on epileptic children and its effect on bone metabolism[J]. J Hebei Med Univ, 2015,36(9):1076-1079. In Chinese.
14. Medarevic D, Kachrimanis K, Djuric′ Z, et al.Influence of hydrophilic polymers on the complexation of carbamazepine with hydroxypropyl-beta-cyclodextrin[J]. Eur J Pharm Sci,2015,78:273-285.
15. LIU Yong, CHEN ShengLi, LIU Liang, et al. Effects of levetiracetam and carbamazepine on neurocognitive function and bone metabolism in patients with newly diagnosed epilepsy[J]. Mod J Integr Tradit Chin West Med,2016,25(18):1978-1980. In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口